Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA 2439149 C · Owner: Schering Corporation · Inventors: Young, Jonathan R.; Goulet, Mark T.; Nargund, Ravi P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Certain novel 4-substituted N-acylated piperidine derivatives of formula (I) are , agonists of the human melanocortin receptor(s) and in particular, are , selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such , as obesity, diabetes, sexual dysfunction including erectile dysfunction and , female sexual dysfunction, (see formula I)
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 25, 2002 and granted April 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.